.svg){kind=icon}
.svg){kind=icon}
%201.svg){kind=icon}
%201.svg){kind=icon}
.svg){kind=icon}
.svg)
.svg)
Ginger Jin
Ginger Zhe Jin is a Professor of Economics at the University of Maryland, College Park and a Research Associate of the National Bureau of Economic Research. She received her B.S. from the University of Science and Technology of China in 1992, M.A. from the Graduate School of the People’s Bank of China in 1995, and Ph.D. from the University of California Los Angeles in 2000. Her primary fields of research are industrial organisation, health economics, and the economics of family. Most of her research focus on information asymmetry among economic agents and how to provide information to overcome the information problem. The applications she has studied include restaurant hygiene inspections, healthcare organisations, prescription drugs, online trading, scientific publications, and the intrafamilial interaction between parents and children. Since 2009, she started to work on China-related issues, including migration, environment, health, blood donation and e-commerce. Her work has been funded by the National Science Foundation, the National Bureau of Economic Research, and the Alfred P. Sloan Foundation.
.svg)
Drug quality and global trade
There is a perception amongst pharmaceutical experts that some Indian manufacturers and/or their distributors segment the global medicine market into portions that are served by different quality medicines. This column finds that drug quality is poorer among Indian-labelled drugs purchased in African countries than among those purchased in India or middle-income countries. Substandard drugs – non-registered in Africa and containing insufficient amounts of the active ingredient – are the biggest driver of this quality difference.
